Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova, Sergey N Mosolov, Nikolai G Neznanov, Alexander M Reznik, Anatoly B Smulevich, Vladimir A Tochilov, Bryan G Johnson, James A Monn, Darryle D Schoepp. Nat Med 2007
Times Cited: 783
Times Cited: 783
Times Cited
Times Co-cited
Similarity
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
33
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
B Moghaddam, B W Adams. Science 1998
B Moghaddam, B W Adams. Science 1998
32
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
Bruce J Kinon, Brian A Millen, Lu Zhang, David L McKinzie. Biol Psychiatry 2015
Bruce J Kinon, Brian A Millen, Lu Zhang, David L McKinzie. Biol Psychiatry 2015
30
Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
26
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao,[...]. BMC Psychiatry 2014
AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao,[...]. BMC Psychiatry 2014
30
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
James Maksymetz, Sean P Moran, P Jeffrey Conn. Mol Brain 2017
James Maksymetz, Sean P Moran, P Jeffrey Conn. Mol Brain 2017
28
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
19
AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
42
Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
18
Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
17
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
David H Adams, Bruce J Kinon, Simin Baygani, Brian A Millen, Isabella Velona, Sara Kollack-Walker, David P Walling. BMC Psychiatry 2013
David H Adams, Bruce J Kinon, Simin Baygani, Brian A Millen, Isabella Velona, Sara Kollack-Walker, David P Walling. BMC Psychiatry 2013
25
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.
David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gomez. Schizophr Res Treatment 2014
David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gomez. Schizophr Res Treatment 2014
32
Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
D C Javitt, S R Zukin. Am J Psychiatry 1991
14
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
18
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.
Bita Moghaddam, Daniel Javitt. Neuropsychopharmacology 2012
Bita Moghaddam, Daniel Javitt. Neuropsychopharmacology 2012
14
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
13
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
J Cartmell, J A Monn, D D Schoepp. J Pharmacol Exp Ther 1999
J Cartmell, J A Monn, D D Schoepp. J Pharmacol Exp Ther 1999
13
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
13
A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Ruggero Galici, Nicholas G Echemendia, Alice L Rodriguez, P Jeffrey Conn. J Pharmacol Exp Ther 2005
Ruggero Galici, Nicholas G Echemendia, Alice L Rodriguez, P Jeffrey Conn. J Pharmacol Exp Ther 2005
13
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Matthew J Fell, Kjell A Svensson, Bryan G Johnson, Darryle D Schoepp. J Pharmacol Exp Ther 2008
Matthew J Fell, Kjell A Svensson, Bryan G Johnson, Darryle D Schoepp. J Pharmacol Exp Ther 2008
13
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
11
A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
11
Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
11
Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.
Miguel Fribourg, José L Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K Adney, Candice Hatcher, José M Eltit,[...]. Cell 2011
Miguel Fribourg, José L Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K Adney, Candice Hatcher, José M Eltit,[...]. Cell 2011
11
Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.
James A Monn, Lourdes Prieto, Lorena Taboada, Concepcion Pedregal, Junliang Hao, Matt R Reinhard, Steven S Henry, Paul J Goldsmith, Christopher D Beadle, Lesley Walton,[...]. J Med Chem 2015
James A Monn, Lourdes Prieto, Lorena Taboada, Concepcion Pedregal, Junliang Hao, Matt R Reinhard, Steven S Henry, Paul J Goldsmith, Christopher D Beadle, Lesley Walton,[...]. J Med Chem 2015
24
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
15
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
James A Monn, Lourdes Prieto, Lorena Taboada, Junliang Hao, Matthew R Reinhard, Steven S Henry, Christopher D Beadle, Lesley Walton, Teresa Man, Helene Rudyk,[...]. J Med Chem 2015
James A Monn, Lourdes Prieto, Lorena Taboada, Junliang Hao, Matthew R Reinhard, Steven S Henry, Christopher D Beadle, Lesley Walton, Teresa Man, Helene Rudyk,[...]. J Med Chem 2015
34
A family of metabotropic glutamate receptors.
Y Tanabe, M Masu, T Ishii, R Shigemoto, S Nakanishi. Neuron 1992
Y Tanabe, M Masu, T Ishii, R Shigemoto, S Nakanishi. Neuron 1992
10
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
Meng-Lin Li, Xi-Quan Hu, Feng Li, Wen-Jun Gao. Prog Neuropsychopharmacol Biol Psychiatry 2015
Meng-Lin Li, Xi-Quan Hu, Feng Li, Wen-Jun Gao. Prog Neuropsychopharmacol Biol Psychiatry 2015
25
Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.
Hiba Salih, Ion Anghelescu, Iva Kezic, Vikash Sinha, Eef Hoeben, Luc Van Nueten, Heidi De Smedt, Peter De Boer. J Psychopharmacol 2015
Hiba Salih, Ion Anghelescu, Iva Kezic, Vikash Sinha, Eef Hoeben, Luc Van Nueten, Heidi De Smedt, Peter De Boer. J Psychopharmacol 2015
31
Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
10
Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
10
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
10
NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.
Houman Homayoun, Bita Moghaddam. J Neurosci 2007
Houman Homayoun, Bita Moghaddam. J Neurosci 2007
10
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.
Mitsumasa Kurita, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, Nagahide Takahashi,[...]. Nat Neurosci 2012
Mitsumasa Kurita, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, Nagahide Takahashi,[...]. Nat Neurosci 2012
10
The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Anna Sławińska, Joanna M Wierońska, Katarzyna Stachowicz, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Magdalena Kusek, Krzysztof Tokarski, Darío Doller,[...]. Br J Pharmacol 2013
Anna Sławińska, Joanna M Wierońska, Katarzyna Stachowicz, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Magdalena Kusek, Krzysztof Tokarski, Darío Doller,[...]. Br J Pharmacol 2013
27
Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.
D S Lorrain, C S Baccei, L J Bristow, J J Anderson, M A Varney. Neuroscience 2003
D S Lorrain, C S Baccei, L J Bristow, J J Anderson, M A Varney. Neuroscience 2003
10
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
Jerri M Rook, Zixiu Xiang, Xiaohui Lv, Ayan Ghoshal, Jonathan W Dickerson, Thomas M Bridges, Kari A Johnson, Daniel J Foster, Karen J Gregory, Paige N Vinson,[...]. Neuron 2015
Jerri M Rook, Zixiu Xiang, Xiaohui Lv, Ayan Ghoshal, Jonathan W Dickerson, Thomas M Bridges, Kari A Johnson, Daniel J Foster, Karen J Gregory, Paige N Vinson,[...]. Neuron 2015
12
Regulation of neurotransmitter release by metabotropic glutamate receptors.
J Cartmell, D D Schoepp. J Neurochem 2000
J Cartmell, D D Schoepp. J Neurochem 2000
9
9
Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
11
An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
Darrick T Balu, Yan Li, Shunsuke Takagi, Kendall Taylor Presti, Teniel S Ramikie, Jerri M Rook, Carrie K Jones, Craig W Lindsley, P Jeffrey Conn, Vadim Y Bolshakov,[...]. Neuropsychopharmacology 2016
Darrick T Balu, Yan Li, Shunsuke Takagi, Kendall Taylor Presti, Teniel S Ramikie, Jerri M Rook, Carrie K Jones, Craig W Lindsley, P Jeffrey Conn, Vadim Y Bolshakov,[...]. Neuropsychopharmacology 2016
21
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
M L Woolley, D J Pemberton, S Bate, C Corti, D N C Jones. Psychopharmacology (Berl) 2008
M L Woolley, D J Pemberton, S Bate, C Corti, D N C Jones. Psychopharmacology (Berl) 2008
9
Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Shigeyuki Chaki. Eur J Pharmacol 2010
Shigeyuki Chaki. Eur J Pharmacol 2010
18
A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.
D Bugarski-Kirola, A Wang, D Abi-Saab, T Blättler. Eur Neuropsychopharmacol 2014
D Bugarski-Kirola, A Wang, D Abi-Saab, T Blättler. Eur Neuropsychopharmacol 2014
15
Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
12
The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.
J Cartmell, J A Monn, D D Schoepp. Eur J Pharmacol 2000
J Cartmell, J A Monn, D D Schoepp. Eur J Pharmacol 2000
10
The metabotropic glutamate receptors: structure and functions.
J P Pin, R Duvoisin. Neuropharmacology 1995
J P Pin, R Duvoisin. Neuropharmacology 1995
8
Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
J A Monn, M J Valli, S M Massey, R A Wright, C R Salhoff, B G Johnson, T Howe, C A Alt, G A Rhodes, R L Robey,[...]. J Med Chem 1997
J A Monn, M J Valli, S M Massey, R A Wright, C R Salhoff, B G Johnson, T Howe, C A Alt, G A Rhodes, R L Robey,[...]. J Med Chem 1997
8
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.